Image Credit: Canva
Most people are aware of type 1 and type 2 diabetes, but did you know there is a type 3 diabetes as well! It is a more obscure term. Although it is not an accepted medical diagnosis, type 3 diabetes has been discussed in the literature as a possible relationship between insulin resistance in the brain and Alzheimer's disease. This link has been described to help explain how metabolic disorders impact brain health, causing cognitive decline and dementia.
Type 3 diabetes is more of a misnomer because it should not be confused with type 3c diabetes, which relates to pancreatic dysfunction. The term "type 3 diabetes," on the other hand, has been loosely used by some scientists to analogously propose that Alzheimer's disease is strongly implicated with insulin resistance in the brain.
This concept was conceptualized by Dr. Suzanne de la Monte and Dr. Jack Wands of Brown University in the year 2008. This hypothesis postulated that Alzheimer's disease may be called type 3 diabetes for it bears many similarities with glucose metabolism disorder type 2 diabetes. Their concept arises from the basic principle that insulin is fundamental to blood sugar regulation, but it is also the case with the brain. When brain cells become insulin-resistant, they lose access to glucose, impairing their function.
Research published in the Journal of Diabetes Science and Technology supports this hypothesis by indicating that insulin resistance can be a significant contributor to the occurrence of dementia, also referred to as Alzheimer's. The symptoms of memory loss and diminished reasoning are associated with impaired glucose metabolism in the body, especially in the cerebral tissue.
Although type 3 diabetes is not a "medical term," its symptoms correlate well with Alzheimer's diseases that are known to reduce the ability to think in an efficient manner and bring down brain health. These signs are:
- Loss of memory, especially short-term.
- Poor judgment and judgment ability
- Failure in recognizing people or places familiar once.
- Failure in the process of reading, writing or processing numbers
- Anxiety, agitation, or mood changes.
- Disorganized thoughts or confusion
- Lack of impulse control
As the disease advances, patients may be afflicted with severe complications including an inability to swallow or control their bodily functions. In the final stages, most patients die from fatal complications such as aspiration pneumonia.
This may not be well understood with regards to type 3 diabetes, or the exact link between insulin resistance and Alzheimer's disease. Some identified contributing factors include the following:
Insulin acts as an important regulatory mechanism of brain functions such as memory and cognition. The reduction in insulin signaling may impair metabolism of brain cells, thus bringing about neurodegeneration.
These diseases show a strong relationship and those individuals diagnosed with type 2 diabetes have double chances of getting Alzheimer's. In the two, the main causes can be chronic inflammation, oxidative stress, and a defect in glucose metabolism.
Insulin resistance associated with obesity, stress, and an unhealthy diet is considered a cause that may increase the chances of Alzheimer's disease.
Researches in Frontiers in Neuroscience and The Lancet Neurology have also highlighted that drugs used for antidiabetic medication may be crucial for the prevention or at least slowing down the course of Alzheimer's.
In 2022, in a study in Pharmaceuticals, researchers studied biomarker uptake in brain regions implicated in the faulty uptake and metabolism of blood sugar in Alzheimer’s patients.
Emerging Therapies
Research into such treatments as intranasal insulin has also been promising. Intranasal delivery of insulin directly to the brain has been reported to enhance glucose uptake by brain cells, improve memory, and boost cognitive performance. While such clinical trials have been shown to be successful, additional research is needed for safety and efficacy.
Medications
For patients being aggressive or agitated, antipsychotic drugs may be prescribed; however, therapies such as cognitive rehabilitation as well as cognitive stimulation therapy serve to preserve memory and executive function.
Lifestyle Interventions
Diet, exercise, and stress management are critical in preventing and managing insulin resistance. A review in the Journal of Alzheimer's Disease also highlighted the benefits of Kirtan Kriya meditation, which can regulate genes involved in insulin and glucose metabolism, improve sleep, and reduce inflammation.
Although type 3 diabetes is not officially recognized, its connection to Alzheimer’s disease underscores the importance of proactive measures for brain health. Some prevention strategies include:
1. Healthy Diet
Consuming a balanced diet rich in antioxidants, whole grains, and healthy fats may support brain health.
2. Regular Exercise
Physical activity improves insulin sensitivity, reduces inflammation, and enhances overall metabolic health.
3. Stress Reduction
Mindfulness practices, including meditation, have been shown to lower stress levels, which can reduce the risk of cognitive decline.
The term type 3 diabetes brings out the complex relationship between metabolic disorders and brain health. Even though it is not a recognized medical condition, the concept emphasizes the crucial role of insulin in brain function and its possible contribution to Alzheimer's disease. Continued research will hopefully provide hope for therapies such as intranasal insulin and lifestyle modifications.
Credit: AI
When we think of dialysis, we often picture a machine filtering blood and keeping patients alive. What rarely comes to mind is the small blood vessel in the arm that makes the entire process possible.
For every patient on haemodialysis, the arteriovenous (AV) fistula is quite literally a lifeline. Without it, dialysis cannot be performed effectively. Yet, despite being one of the most important parts of treatment, fistula care remains one of the least understood aspects of kidney disease.
This silent gap in awareness is costing patients their lifeline.
India adds nearly 2.2 lakh new patients with end-stage kidney disease every year, creating a demand for over 3.4 crore dialysis sessions annually.
One of the biggest challenges we see in clinical practice is that patients often seek medical help only after the fistula has already stopped functioning.
The warning signs are usually ignored.
The vibration over the fistula becomes weaker. The arm begins to swell. Bleeding continues longer than usual after dialysis. Needle insertion becomes increasingly difficult. Sometimes dialysis itself becomes less effective.
By the time patients reach an interventional radiologist or vascular specialist, the fistula may already have developed significant narrowing (stenosis) or complete blockage.
Unfortunately, many of these complications are preventable if detected early.
In our experience, nearly 30% of patients eventually lose their fistula because they report too late, when timely intervention could have salvaged access.
Also read: COVID Spikes In India: Experts Allay Fears, Stress Vaccination And Masks
Unlike diabetes or blood pressure, there is no widespread public awareness around fistula surveillance.
Many dialysis patients receive instructions on medicines and dialysis schedules but very little education on how to examine their fistula every day.
There is also no universally implemented patient education protocol across dialysis centres, leading to inconsistent awareness about fistula care.
The result is simple: patients unknowingly damage the very access that keeps them alive.
Patients should examine their fistula daily.
A healthy fistula has a continuous buzzing sensation or “thrill.” If this vibration becomes weak or disappears, medical attention should be sought immediately.
Similarly, swelling of the arm, redness, prolonged bleeding after dialysis, pain around the fistula, or difficulty during needle insertion should never be dismissed as routine.
These are early warning signs - not inconveniences.
Also read: Omicron Sub-Lineages Likely Behind COVID Surge In India: Why Deaths Are Occurring
These small daily habits can often extend the life of a fistula by years.
One of the greatest advances in dialysis access care is that many fistula problems no longer require open surgery.
If narrowing is detected early, minimally invasive image-guided procedures such as fistuloplasty (balloon angioplasty) can restore blood flow, preserve the existing fistula and help patients continue dialysis without interruption.
The key, however, is timing.
A fistula that is evaluated early is often salvageable.
A fistula ignored for weeks may not be.
Every successful fistula represents months of planning, surgery and healing. Losing it means additional procedures, temporary catheters, higher infection risk, increased costs and emotional distress for patients already living with chronic kidney disease.
As doctors, we have become increasingly skilled at creating dialysis access.
The next challenge is ensuring patients know how to protect it.
Because for someone living with kidney failure, the fistula is not just another blood vessel.
It is the lifeline that keeps life moving.
By Dr. Avik Bhattacharyya, Senior Consultant - Interventional Radiology, CK Birla Hospitals, CMRI
Credit: iStock
GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and liraglutide, best known for regulating appetite and aiding weight loss, may also help reduce symptoms of binge eating disorder (BED), which affects more than 17 million people worldwide, according to a new study.
The systematic review and meta-analysis, published in the journal eClinicalMedicine, found that GLP-1 drugs, with semaglutide as its key ingredient, reduced binge eating episodes, loss-of-control eating and emotional eating, highlighting their potential role in treating binge eating disorder alongside obesity.
Binge eating disorder affects over 17 million people globally, and around two-thirds of people with the condition also live with overweight or obesity. It is also common among individuals seeking weight-loss treatment.
"Binge eating disorder, where people regularly eat an excessive amount of food while feeling they have lost control, is common and highly impairing, affecting over 17 million people worldwide," said lead author Dr Ilaria Costantini from the Psychiatry Department at University College London (UCL), UK.
"But treatment options are limited and there are currently no approved medications, so there remains a need for better ways to help people living with this condition. We found evidence that weight loss drugs may help to manage some key symptoms of binge eating disorder," Costantini added.
Also read: Babies Without Vitamin K Shot At Higher Risk Of Brain Bleeding: Study
The researchers analyzed 25 randomized controlled trials conducted across 12 countries on four continents, involving 8,069 participants.
The trials evaluated GLP-1 drugs that target the appetite-regulating hormone GLP-1, including semaglutide (marketed as Ozempic or Wegovy), tirzepatide (Mounjaro) and liraglutide.
These medications suppress appetite by acting on the central nervous system and insulin secretion, delay stomach emptying, and may also influence brain pathways involved in reward and impulse control.
Compared with placebo or other treatments, people taking GLP-1 drugs reported:
Read More: Obesity-Driven CKM Syndrome A Growing Public Health Threat, Warns American Heart Association
The researchers also found that participants taking GLP-1 drugs reported greater cognitive or dietary restraint, meaning they made more deliberate efforts to limit what they ate.
The benefits extended beyond weight loss, with improvements seen in several behaviors associated with binge eating disorder.
While increased dietary restraint was observed, the researchers cautioned that it remains unclear whether this represents healthy self-regulation or a more rigid, potentially harmful eating pattern that could worsen binge eating over time.
"From the evidence available, we cannot say whether the increase in dietary restraint reflects a positive and helpful form of self-regulation or if it is a more dysfunctional pattern of eating. We hope that future research can clarify whether or not taking weight loss drugs might contribute to more pathological forms of eating restriction such as meal skipping," said Izzy Emptage from UCL Psychiatry.
The researchers said GLP-1 drugs could become an important addition to treatment plans for binge eating disorder when used alongside psychological therapies and social support.
However, they also highlighted important limitations. Most of the studies included in the review had a high risk of bias, were funded by pharmaceutical companies, and rarely included participants with a clinical diagnosis of binge eating disorder, reducing the certainty of the findings.
"GLP-1s may offer a promising additional treatment option for people living with both binge eating and obesity," the researchers said, while stressing that these drugs "should not be viewed as a standalone solution to binge eating disorder."
They added that larger, independently funded clinical trials are needed before these medications can be routinely recommended for treating binge eating disorders.
Credit: AI
What if staying younger has less to do with expensive anti-aging products and more to do with spending time appreciating the culture. A new study suggests that regular cultural outings may be linked to slower biological aging.
Expect an unexpected addition to the list of healthy lifestyle habits. Researchers recently found that older adults who frequently visited museums, theaters, cinemas, concerts, and art galleries physically functioned as if they were about three years younger than those who didn’t take part in such activities.
Published in the Journal of Epidemiology and Community Health, the researchers say that cultural interaction appears to be associated with a younger physiological age, although the study does not prove that cultural activities directly contribute to slow aging.
The study analyzed data from 1,899 adults aged 50 years and older who participated in the English Longitudinal Study of Ageing. Participants reported how often they:
Researchers also assessed 10 health indicators, including:
These measures were combined to ascertain each participant's physiological age.
People who participated in cultural activities every few months or more had an average physiological age of 66.9 years, compared with 69.9 years among those with lower levels of cultural engagement, a difference of roughly three biological years.
The researchers also found that every one-point increase in a person's cultural engagement score was associated with approximately a 31-day reduction in physiological age, even after accounting for income, employment, and chronic health conditions.
Although the study wasn't designed to identify a direct cause, the researchers suggest several possible explanations that can help reduce biological age. Cultural activities may help:
Interestingly, the researchers noted that the association between cultural engagement and slower aging was comparable to the benefits seen with frequent physical activity, highlighting that healthy aging may involve much more than exercise alone.
The latest findings add to a growing body of research suggesting that spending time on cultural activities may benefit both the brain and the body as people age.
Previous studies have found that older adults who regularly visit museums, art galleries, theaters, concerts, and similar cultural spots may have a lower risk of dementia, experience slower cognitive decline, and even live longer than those who rarely engage in such activities.
For example, a 2019 study published in The BMJ reported that adults over 50 who participated in cultural activities every few months or more had a 31% lower risk of death during a 14-year follow-up compared with those who never took part.
Another study from University College London found that frequent museum visits were associated with a reduced risk of developing dementia over the following decade.
© 2024 Bennett, Coleman & Company Limited